Market research
APLLTD.NSE Alembic Pharmaceuticals Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 161B
- P/E ratio
- 23.17
- Analyst target
- 949.3
- Dividend yield
- 0.0%
- Beta
- 0.3
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE901L01018
- Market cap
- 161B
- P/E ratio
- 23.17
- Analyst target
- 949.3
- Dividend yield
- 0.0%
- Beta
- 0.3
About
About Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the APLLTD.NSE discussion.
5 years, 5 months ago
Alembic Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 0.6% above its 200 day moving average.
From a valuation standpoint, the stock is 24.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.6.
Alembic Pharmaceuticals Limited's total revenue rose by 8.7% to $13B since the same quarter in the previous year.
Its net income has increased by 24.9% to $3B since the same quarter in the previous year.
Finally, its free cash flow grew by 582.7% to $9B since the same quarter in the previous year.
Based on the above factors, Alembic Pharmaceuticals Limited gets an overall score of 5/5.